Designer Glycopeptides for Cytotoxic T Cell–based Elimination of Carcinomas

Content Provider	Semantic Scholar
Author	Xu, Yanfei Gendler, Sandra J. Franco, Alessandra
Copyright Year	2004
Abstract	Tumors express embryonic carbohydrate antigens called tumor-associated carbohydrate antigens (TACA). TACA-containing glycopeptides are appealing cytotoxic T cell (CTL)-based vaccines to prevent or treat cancer because the same sugar moieties are expressed in a variety of tumors, rendering a vaccination strategy applicable in a large population. Here we demonstrate that by using glycopeptides with high affinity for the major histocompatibility complex and glycosylated in a position corresponding to a critical T cell receptor (TcR) contact, it is possible to induce anti-TACA CTL in vivo. In the current study we show that designer glycopeptides containing the Thomsen-Freidenreich (TF) antigen (beta-Gal-[1-->3]-alpha-GalNAc-O-serine) are immunogenic in vivo and generate TF-specific CTL capable of recognizing a variety of tumor cells in vitro including a MUC1-expressing tumor. The fine specificity of the TF-specific CTL repertoire indicates that the TcR recognize the glycosylated amino acid residue together with TF in a conventional major histocompatibility complex class I-restricted fashion. These results have high potential for immunotherapy against a broad range of tumors.
Starting Page	707
Ending Page	716
Page Count	10
File Format	PDF HTM / HTML
PubMed reference number	14993254v1
Volume Number	199
Journal	The Journal of experimental medicine
Alternate Webpage(s)	http://jem.rupress.org/content/jem/199/5/707.full.pdf
Language	English
Access Restriction	Open
Subject Keyword	Adrenergic beta-Agonists Amino Acids Antigens, Tumor-Associated, Carbohydrate Biomarkers, Tumor Carbohydrates Cellular Phone Cytotoxic T-Lymphocytes Glycopeptides HIV Antigens Immunotherapy In Vitro [Publication Type] Leukemia, B-Cell Neoplasms Sugars T-Cell Receptor Thomsen-Friedenreich antigen
Content Type	Text
Resource Type	Article